Fate therapeutics presents new phase 1 clinical data of ft819 off-the-shelf, car t-cell product candidate for systemic lupus erythematosus

All three patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained b-cell depletion with favorable safety profile

CAR Ratings Summary

CAR Quant Ranking